{"id":"https://openalex.org/W4365810285","doi":"https://doi.org/10.1111/cts.13524","title":"Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants","display_name":"Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants","publication_year":2023,"publication_date":"2023-04-15","ids":{"openalex":"https://openalex.org/W4365810285","doi":"https://doi.org/10.1111/cts.13524","pmid":"https://pubmed.ncbi.nlm.nih.gov/37060187","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10339699"},"language":"en","primary_location":{"id":"doi:10.1111/cts.13524","doi":"https://doi.org/10.1111/cts.13524","is_oa":true,"landing_page_url":"https://doi.org/10.1111/cts.13524","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.13524","source":{"id":"https://openalex.org/S106654227","display_name":"Clinical and Translational Science","issn_l":"1752-8054","issn":["1752-8054","1752-8062"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical and Translational Science","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.13524","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024527668","display_name":"Sibel Ucpinar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sibel Ucpinar","raw_affiliation_strings":["Department of Pharmacokinetics, Dynamics, and Metabolism, Sanofi US, Inc., Bridgewater, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacokinetics, Dynamics, and Metabolism, Sanofi US, Inc., Bridgewater, New Jersey, USA","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012385241","display_name":"Patrick F. Smith","orcid":"https://orcid.org/0000-0002-6003-0805","observed_orcids":["https://orcid.org/0000-0002-6003-0805"]},"institutions":[{"id":"https://openalex.org/I4210119960","display_name":"Certara (United States)","ror":"https://ror.org/02kxjqp24","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119960"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick F. Smith","raw_affiliation_strings":["Integrated Drug Development, Certara, Parsippany, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integrated Drug Development, Certara, Parsippany, New Jersey, USA","institution_ids":["https://openalex.org/I4210119960"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100408800","display_name":"Long Li","orcid":"https://orcid.org/0000-0003-1670-4523","observed_orcids":["https://orcid.org/0000-0003-1670-4523"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Li Long","raw_affiliation_strings":["Clinical and Pharmaceutical Development, Kezar Life Sciences, South San Francisco, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical and Pharmaceutical Development, Kezar Life Sciences, South San Francisco, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101868664","display_name":"Fujun Li","orcid":"https://orcid.org/0000-0003-0365-6024","observed_orcids":["https://orcid.org/0000-0003-0365-6024"]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Fujun Li","raw_affiliation_strings":["Analytical and Pharmaceutical Development, Sanofi US, Inc., Bridgewater, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analytical and Pharmaceutical Development, Sanofi US, Inc., Bridgewater, New Jersey, USA","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Hui Yan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hui Yan","raw_affiliation_strings":["Analytical and Pharmaceutical Development, Sanofi US, Inc., Bridgewater, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analytical and Pharmaceutical Development, Sanofi US, Inc., Bridgewater, New Jersey, USA","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jyoti Wadhwa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jyoti Wadhwa","raw_affiliation_strings":["Clinical and Pharmaceutical Development, Kezar Life Sciences, South San Francisco, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical and Pharmaceutical Development, Kezar Life Sciences, South San Francisco, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069738030","display_name":"Katherine A. Chu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katherine A. Chu","raw_affiliation_strings":["Analytical and Pharmaceutical Development, Sanofi US, Inc., Bridgewater, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analytical and Pharmaceutical Development, Sanofi US, Inc., Bridgewater, New Jersey, USA","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064779408","display_name":"Jin Shu","orcid":"https://orcid.org/0000-0002-0622-3219","observed_orcids":["https://orcid.org/0000-0002-0622-3219"]},"institutions":[{"id":"https://openalex.org/I4210151032","display_name":"Principia Biopharma (United States)","ror":"https://ror.org/05fw76c12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151032"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jin Shu","raw_affiliation_strings":["Principia Biopharma Inc., South San Francisco, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Principia Biopharma Inc., South San Francisco, California, USA","institution_ids":["https://openalex.org/I4210151032"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112198581","display_name":"Philip A. Nunn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151032","display_name":"Principia Biopharma (United States)","ror":"https://ror.org/05fw76c12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151032"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip Nunn","raw_affiliation_strings":["Principia Biopharma Inc., South San Francisco, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Principia Biopharma Inc., South San Francisco, California, USA","institution_ids":["https://openalex.org/I4210151032"]}]},{"author_position":"last","author":{"id":null,"display_name":"Mengyao Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mengyao Li","raw_affiliation_strings":["Department of Pharmacokinetics, Dynamics, and Metabolism, Sanofi US, Inc., Bridgewater, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacokinetics, Dynamics, and Metabolism, Sanofi US, Inc., Bridgewater, New Jersey, USA","institution_ids":["https://openalex.org/I4210111804"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5101868664"],"corresponding_institution_ids":["https://openalex.org/I4210111804"],"apc_list":{"value":3300,"currency":"USD","value_usd":3300},"apc_paid":{"value":3300,"currency":"USD","value_usd":3300},"fwci":3.9374,"has_fulltext":true,"cited_by_count":21,"citation_normalized_percentile":{"value":0.9451595,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"16","issue":"7","first_page":"1210","last_page":"1219"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9648000001907349,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9648000001907349,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.006399999838322401,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rilzabrutinib","display_name":"rilzabrutinib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.9710000157356262},{"id":"https://openalex.org/keywords/reversible-covalent-inhibitors","display_name":"reversible covalent inhibitors","score":0.8240000009536743},{"id":"https://openalex.org/keywords/absolute-oral-bioavailability","display_name":"absolute oral bioavailability","score":0.7850000262260437},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.796999990940094},{"id":"https://openalex.org/keywords/absorption","display_name":"absorption","score":0.5529999732971191},{"id":"https://openalex.org/keywords/metabolism","display_name":"metabolism","score":0.7730000019073486},{"id":"https://openalex.org/keywords/excretion","display_name":"excretion","score":0.9789999723434448},{"id":"https://openalex.org/keywords/fecal-excretion","display_name":"fecal excretion","score":0.7900000214576721},{"id":"https://openalex.org/keywords/urinary-excretion","display_name":"urinary excretion","score":0.7850000262260437},{"id":"https://openalex.org/keywords/radiolabeled-drug","display_name":"radiolabeled drug","score":0.699999988079071},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.7699999809265137}],"concepts":[{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.7716929912567139},{"id":"https://openalex.org/C10146269","wikidata":"https://www.wikidata.org/wiki/Q185557","display_name":"Excretion","level":2,"score":0.6896374225616455},{"id":"https://openalex.org/C125287762","wikidata":"https://www.wikidata.org/wiki/Q1758948","display_name":"Absorption (acoustics)","level":2,"score":0.536146879196167},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.487341970205307},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.4683624505996704},{"id":"https://openalex.org/C90059517","wikidata":"https://www.wikidata.org/wiki/Q423572","display_name":"Bruton's tyrosine kinase","level":4,"score":0.4663044214248657},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.45877087116241455},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3805568218231201},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32694369554519653},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.31284481287002563},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.22872886061668396},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.11234685778617859},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.057385921478271484},{"id":"https://openalex.org/C159985019","wikidata":"https://www.wikidata.org/wiki/Q181790","display_name":"Composite material","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000092004","descriptor_name":"Tyrosine Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002250","descriptor_name":"Carbon Radioisotopes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1111/cts.13524","doi":"https://doi.org/10.1111/cts.13524","is_oa":true,"landing_page_url":"https://doi.org/10.1111/cts.13524","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.13524","source":{"id":"https://openalex.org/S106654227","display_name":"Clinical and Translational Science","issn_l":"1752-8054","issn":["1752-8054","1752-8062"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical and Translational Science","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10339699","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10339699","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10339699/pdf/CTS-16-1210.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Transl Sci","raw_type":"Text"},{"id":"pmid:37060187","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37060187","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical and translational science","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:doaj.org/article:e8f901b053fc4c77b57444a1f51b046f","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/e8f901b053fc4c77b57444a1f51b046f","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Clinical and Translational Science, Vol 16, Iss 7, Pp 1210-1219 (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1111/cts.13524","doi":"https://doi.org/10.1111/cts.13524","is_oa":true,"landing_page_url":"https://doi.org/10.1111/cts.13524","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.13524","source":{"id":"https://openalex.org/S106654227","display_name":"Clinical and Translational Science","issn_l":"1752-8054","issn":["1752-8054","1752-8062"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical and Translational Science","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4365810285.pdf","grobid_xml":"https://content.openalex.org/works/W4365810285.grobid-xml"},"referenced_works_count":15,"referenced_works":["https://openalex.org/W152943885","https://openalex.org/W1526377515","https://openalex.org/W2005524204","https://openalex.org/W2022969158","https://openalex.org/W2072320300","https://openalex.org/W2081711436","https://openalex.org/W2082979826","https://openalex.org/W2093522627","https://openalex.org/W2094295085","https://openalex.org/W2101858940","https://openalex.org/W2258682798","https://openalex.org/W2676228912","https://openalex.org/W2791299132","https://openalex.org/W3158535098","https://openalex.org/W4223930092"],"related_works":["https://openalex.org/W4376616415","https://openalex.org/W4225390115","https://openalex.org/W1690318541","https://openalex.org/W2008297056","https://openalex.org/W4321376060","https://openalex.org/W4417044104","https://openalex.org/W2025703773","https://openalex.org/W3192458591","https://openalex.org/W2016641526","https://openalex.org/W4386252492"],"abstract_inverted_index":{"Abstract":[0],"This":[1],"single\u2010center,":[2],"open\u2010label,":[3],"non\u2010randomized,":[4],"two\u2010part,":[5],"phase":[6],"I":[7],"study":[8,244],"was":[9,107,114,176,206,225,237],"conducted":[10],"(1)":[11],"to":[12,47,131],"evaluate":[13],"the":[14,49,153,208,246,249],"absolute":[15,99,250],"oral":[16,36,60,105,119,154,182,230],"bioavailability":[17,100,251],"of":[18,28,38,55,64,80,101,121,139,148,160,184,196,203,223,234,242,248,254],"rilzabrutinib":[19,41,57,104,113,122,175,236,255],"400":[20,39,102,123],"mg":[21,40,103,124,186],"tablet":[22,42,106,125],"following":[23,58,152,180],"an":[24],"i.v.":[25,157],"microtracer":[26,158],"dose":[27,37,61,120,155,159,183],"~100":[29,161],"\u03bcg":[30,162],"[14C]\u2010rilzabrutinib":[31,65,187],"(~1":[32],"\u03bcCi)":[33],"and":[34,45,52,156,167,216,221,252,256],"single":[35,59,118,181],"(part":[43,76],"1),":[44],"(2)":[46],"characterize":[48],"absorption,":[50],"metabolism,":[51],"excretion":[53,233],"(AME)":[54],"14C\u2010radiolabeled":[56],"(300":[62],"mg)":[63],"(~1000":[66],"\u03bcCi;":[67],"administered":[68],"as":[69],"a":[70,127,190],"liquid)":[71],"in":[72,89,95,207,227],"healthy":[73],"male":[74],"participants":[75],"2).":[77,97],"A":[78],"total":[79,204],"18":[81],"subjects":[82,214,219],"were":[83,164],"enrolled":[84],"(":[85,134],"n":[86,92],"=":[87,93],"8":[88],"part":[90,96,111,173],"1;":[91],"10":[94],"The":[98,144,201,240],"low":[108,238],"(<5%).":[109],"In":[110,172],"1,":[112],"absorbed":[115,178],"rapidly":[116,179],"after":[117,229],"with":[126,189],"median":[128,191],"(range)":[129,192],"time":[130],"maximum":[132],"concentration":[133],"T":[135,193],"max":[136,194],")":[137],"value":[138,195],"2.03":[140],"h":[141,198],"(1.83\u20132.50":[142],"h).":[143,200],"geometric":[145],"mean":[146],"(coefficient":[147],"variation)":[149],"terminal":[150],"half\u2010life":[151],"[14C]\u2010rilzabrutinib,":[163],"3.20":[165],"(51.0%)":[166],"1.78":[168],"(37.6%)":[169],"h,":[170],"respectively.":[171],"2,":[174],"also":[177],"300":[185],"solution":[188],"1.00":[197],"(1.00\u20132.00":[199],"majority":[202],"radioactivity":[205,224],"feces":[209],"for":[210],"both":[211],"non\u2010bile":[212],"collection":[213,218],"(92.9%)":[215],"bile":[217],"(87.6%),":[220],"~5%":[222],"recovered":[226],"urine":[228],"administration.":[231],"Urinary":[232],"unchanged":[235],"(3.02%).":[239],"results":[241],"this":[243],"advance":[245],"understanding":[247],"AME":[253],"can":[257],"help":[258],"inform":[259],"its":[260],"further":[261],"investigation.":[262]},"counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2023-04-16T00:00:00"}